Thyroid cancer
Drug research and approvals for thyroid cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 205 studies of thyroid cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 12 approved and 6 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 205
- Trials authorized in Canada: 9
- FDA orphan approvals: 12
- EU medicines: 2
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisNCT07914764 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Aug 1, 2026
- Ultrasound-guided Microwave Ablation of Benign Thyroid NodulesNCT07906821 · Not applicable · Chinese University of Hong Kong · starts Aug 31, 2023
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerNCT07874321 · Phase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · starts Sep 20, 2026
- Cross Immune Response Between Breast Carcinoma and Thyroid Autoimmunity: Impact on Prognosis and TreatmentNCT07870148 · Not applicable · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts May 9, 2024
- Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid CancerNCT07777536 · Phase 2 · Fudan University · starts Aug 12, 2026
- Safety and Efficacy of Cryoablation for Thyroid TumorsNCT07776262 · Not applicable · Yukun Luo · starts Feb 9, 2026
- Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid CancerNCT07753499 · Not applicable · The First Affiliated Hospital of Xiamen University · starts Aug 1, 2026
- Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After ThyroidectomyNCT07707401 · Not applicable · Shanghai 6th People's Hospital · starts Sep 9, 2026
- Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsNCT07704658 · Phase 4 · Rigel Pharmaceuticals · starts Mar 4, 2026
Approved 9
- LenvatinibVascular endothelial growth factor receptor inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- Thyrotropin alfaThyroid stimulating hormone receptor agonist
- VandetanibTyrosine-protein kinase SRC inhibitor
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- Sodium iodide
- LiothyronineThyroid hormone receptor agonist
- SelpercatinibTyrosine-protein kinase receptor RET inhibitor
- LevothyroxineThyroid hormone receptor agonist
Phase 3 11
- TrametinibDual specificity mitogen-activated protein kinase kinase 2 inhibitor
- DabrafenibSerine/threonine-protein kinase B-raf inhibitor
- PaclitaxelTubulin inhibitor
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- CarboplatinDNA inhibitor
- SelumetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Iodine
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Thyroid
- FosbretabulinTubulin inhibitor
- Fibrin
Phase 2 12 of 65
- EverolimusFK506-binding protein 1A inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
- FludeoxyglucoseDiagnostic agent
- CapecitabineThymidylate synthase inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- VemurafenibSerine/threonine-protein kinase B-raf inhibitor
- CyclophosphamideDNA inhibitor
- SurufatinibFibroblast growth factor receptor 1 inhibitor
- EfatutazonePeroxisome proliferator-activated receptor gamma agonist
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
Phase 1 or earlier 12 of 19
- PP-F11N lutetium
- DacarbazineDNA inhibitor
- Fludarabine
- LapatinibReceptor protein-tyrosine kinase erbB-2 inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- AldesleukinInterleukin-2 receptor agonist
- AdalimumabTNF-alpha inhibitor
- FamotidineHistamine H2 receptor antagonist
- ThyroglobulinIodine storage agent
- SapanisertibSerine/threonine-protein kinase mTOR inhibitor
- TovorafenibRAF serine/threonine protein kinase inhibitor
- PlixorafenibSerine/threonine-protein kinase B-raf inhibitor
How its trials ended
749 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 127 whose ending is known, 35% met their primary endpoint, 12% missed it and 53% stopped early.
- Ongoing26335%
- Completed, result not reported23231%
- Status unknown12717%
- Met its primary endpoint456%
- Stopped: other or unclear345%
- Missed its primary endpoint152%
- Stopped: enrollment or feasibility142%
- Stopped: lack of efficacy81%
- Stopped: funding51%
- Stopped: sponsor or business decision41%
- Stopped: safety2<1%
| Apr 26, 2023 | Study of talazoparib for metastatic relapsed settle tumour: a pediatric oncology precision medicine studyTalazoparib | C17 Council | Closed |
| Apr 13, 2022 | A phase III, randomized, open-label, study of pralsetinib versus standard of care for treatment of ret-mutated medullary thyroid cancer (acceleret mtc)Pralsetinib (RO7499790)/ Vandetanib/ Cabozantinib | Roche | Pending |
| Aug 26, 2021 | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients…Dabrafenib (DRB436) / Trametinib (TMT212) | Novartis Pharmaceuticals | Ongoing |
| Feb 7, 2020 | A multicenter, randomized, open-label, phase 3 trial comparing selpercatinib to physicians choice of cabozantinib or vandetanib in patients with progressive,…Selpercatinib (LY3527723) / Cabozantinib / Vandetanib | Eli Lilly | Ongoing |
| Feb 19, 2019 | A phase 3, randomized, double-blind, placebo-controlled study of cabozantinib (XL184) in subjects with radioiodine-refractory differentiated thyroid cancer who…Cabozantinib / Technetium tc 99M | Exelixis | Closed |
| Dec 14, 2018 | A phase 1/2 study of oral loxo 292 in patients with advanced solid tumors, including ret fusion-positive solid tumors, medullary thyroid cancer and other…Selpercatinib (LOXO-292) | Eli Lilly | Ongoing |
| Nov 23, 2017 | A phase I dose escalation trial to determine if imatinib treatment restores sodium iodide symporter function and sensitivity to radioiodine treatment in…Imatinib | Cross Cancer Institute - Cancer Care Alberta | Ongoing |
| Oct 25, 2017 | A randomized, double-blind study to evaluate the efficacy and safety of cabozantinib (XLL84) at 60 mg/day compared to 140 mg/day in progressive, metastatic…Cabozantinib | Exelixis | Closed |
| Mar 8, 2016 | A multicenter, randomized, double-blind phase 2 trial of lenvatinib (E7080) in subjects with 131i-refractory differentiated thyroid cancer to evaluate whether…Lenvatinib (E7080) | Eisai | Closed |
| May 29, 2024 | RetevmoTreatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET… | Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| Sep 17, 2021 | CabometyxTreatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC)… | Exelixis, Inc. | Approved |
| Dec 1, 2020 | GavretoTreatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer… | Rigel Pharmaceuticals, Inc. | Approved |
| May 8, 2020 | RetevmoRETEVMO is indicated for the treatment of: ¿ Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant… | Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| May 4, 2018 | Tafinlar(r) Capsules a nd Mekinist(r) TabletsMEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid… | Novartis Pharmaceuticals Corporation | Approved |
| May 4, 2018 | Tafinlar(r) Capsules a nd Mekinist(r) TabletsTAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid… | Novartis Pharmaceuticals Corporation | Approved |
| Feb 13, 2015 | LenvimaTreatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer | Eisai, Inc. | Approved |
| Nov 22, 2013 | NexavarTreatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to… | Bayer HealthCare Pharmaceuticals, Inc. | Approved |
| Nov 29, 2012 | CometriqTreatment of progressive, metastatic medullary thyroid cancer (MTC). | Exelixis, Inc. | Approved |
| Apr 6, 2011 | CAPRELSA(r)Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease | Genzyme Corporation | Approved |
| Dec 14, 2007 | ThyrogenFor use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for… | Genzyme Corporation | Approved |
| Nov 30, 1998 | ThyrogenAs an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with… | Genzyme Corporation | Approved |
| Apr 21, 2020 | PentagastrinDiagnostic for the management of medullary thyroid cancer | Exela Pharma Sciences, LLC | Designated |
| Apr 9, 2019 | Autologous chimeric antigen receptor (CAR) T cells…Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer | AffyImmune Therapeutics, Inc. | Designated |
| Sep 2, 2011 | Ribavirin elaidateTreatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer | Translational Therapeutics, Inc. | Designated |
| Feb 16, 2012 | CaprelsaVandetanib | Esteve Pharmaceuticals, S.A. | EMA ↗ |
| Mar 9, 2000 | ThyrogenThyrotropin alfa | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA